The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Due to the critical role of heat shock protein 90 (HSP90) in regulating the stability, activity
and intracellular sorting of its client proteins involved in multiple oncogenic processes …

Conventional photothermal therapy (PTT) irradiates the tumor tissues by elevating the
temperature above 48° C to exert thermal ablation, killing tumor cells. However, thermal …

Since the beginning of history, natural products have been an abundant source of bioactive
molecules for the treatment of different diseases, including cancer. Many allyl derivatives …

The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning
point both in HER2-positive breast cancer treatment and antibody–drug conjugate (ADC) …

The function of the heat shock proteins (HSPsa) is to fold and maintain the proper
conformation of other proteins, referred to as “clients”. HSPs are therefore molecular …

The discovery of some additional properties and functions of reactive oxygen species (ROS),
beyond their toxic effects, provides a novel scenario for the molecular basis and cell …

Introduction Although human epidermal growth factor receptor 2 (HER2) positive or estrogen
receptor (ER) positive breast cancers are treated with clinically validated anti-HER2 or anti …

Hsp90 is a ubiquitous chaperone with important roles in the organization and maturation of
client proteins that are involved in the progression and survival of cancer cells. Multiple …